文献速递胸部肿瘤

EGFR突变非小细胞肺癌系统治疗现状综述

Overview of current systemic management of EGFR-mutant NSCLC.
PubMed 文献 · Ann Oncol · 2018-01-01

本文综述了EGFR突变(外显子19缺失或L858R)非小细胞肺癌一线EGFR-TKI治疗的关键III期研究,证实吉非替尼、厄洛替尼和阿法替尼在无进展生存和缓解率上优于化疗。文章汇总了常见及罕见不良反应的管理,并讨论了罕见突变(G719X、S768I、L861Q)的TKI选择及厄洛替尼联合贝伐珠单抗作为替代一线方案。

要点

  • 一线EGFR-TKI是EGFR敏感突变(19del/L858R)NSCLC的标准治疗。
  • 常见不良反应包括腹泻、痤疮样皮疹、黏膜炎和甲沟炎,需规范管理。
  • 罕见突变(G719X、S768I、L861Q)需特殊选择EGFR-TKI。

核心结论

  • 一线EGFR-TKI(吉非替尼、厄洛替尼或阿法替尼)是EGFR敏感突变NSCLC的标准治疗。
  • 厄洛替尼联合贝伐珠单抗在部分地区被接受为一线替代方案。

研究设计与样本

  • 综述类文章,总结多项III期研究及当前EGFR-TKI在大型试验中的不良反应谱。

主要发现

  • 多项III期研究显示吉非替尼、厄洛替尼或阿法替尼在无进展生存和缓解率上优于化疗。
  • 常见不良反应为腹泻、痤疮样皮疹、黏膜炎和甲沟炎;罕见肝损伤和间质性肺病需早期识别并谨慎管理。
  • 罕见突变(G719X、S768I、L861Q)患者可能需要特殊选择EGFR-TKI。

临床怎么用

  • 一线治疗应基于EGFR突变状态选择EGFR-TKI。
  • 治疗期间需监测并管理腹泻、皮疹、黏膜炎、甲沟炎等不良反应。
  • 对罕见突变患者需个体化选择EGFR-TKI。
  • 厄洛替尼联合贝伐珠单抗可作为部分地区的一线替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs. Other rare side-effects, such as hepatic impairment and interstitial lung disease, should be identified early and managed carefully. Patients with uncommon EGFR mutations, such as G719X, S768I, and L861Q, may require special selection of EGFR TKIs. The combination of erlotinib plus bevacizumab has been accepted in certain parts of the world as an alternative front-line treatment. This review article summarizes the studies leading to the establishment of EGFR TKIs in EGFR-mutant lung cancer patients. The side-effect profiles of the current EGFR TKIs in these large trials are listed, and the management of uncommon EGFR mutations is discussed. Finally, the potential role of combination front-line treatment is discussed.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018. PMID: 29462253. doi:10.1093/annonc/mdx702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。